Care Center2

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

UCLA Health Westwood Medical Plaza

Westwood CA. 90095

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

University Health Network/Toronto General Hospital (Site #: 71121)

Toronto ON.

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Stanford University (Site #: 71141)

Palo Alto CA. 94304

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

University of Minnesota (Site 71151)

Minneapolis MN. 55455

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Vanderbilt University Medical Center (Site #: 71174)

Nashville TN. 37232

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Washington University (Site #: 71157)

St Louis MO. 63130

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

NYU Langone Health (Site #: 71177)

New York NY. 10016

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

University of Pennsylvania (Site #: 71111)

Philadelphia PA. 19104

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Cincinnati Children's Hospital Medical Center (Site #: 71017)

Cincinnati OH. 45229

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

University of California, Los Angeles (Site #: 71123)

Los Angeles CA. 90095

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Cleveland Clinic (Site #: 71101)

Cleveland OH. 44195

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Johns Hopkins (Site #: 71119)

Baltimore MD. 21287

View Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Duke University (Site #: 71139)

Durham NC. 27710

View Details

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

The University of Texas Health Science Center at Houston

Houston TX. 77030

View Details

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

MD Anderson Cancer Center

Houston TX. 77030

View Details

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

University of California San Francisco

San Francisco CA. 94143

View Details

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

University of Michigan

Ann Arbor MI. 48109

View Details

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

University of Kansas

Kansas City KS. 66103

View Details

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

University of Colorado Denver

Aurora CO. 80045

View Details

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Dartmouth Hitchcock Medical Center

Lebanon NH. 03766

View Details

Additional Details

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)